Evidence for a role of advanced glycation end products in atrial fibrillation
International Journal of Cardiology, 06/11/2012RaposeirasRoubin S et al. –
Advanced glycation end–products (AGEs) and sRAGE plasma levels were higher in patients with AF, independently of diabetes mellitus, and they positively correlated with atrial dimensions, indicating a role for the AGE–RAGE axis in the arrhythmogenic structural atrial remodelling.
Ninety–seven consecutive outpatients were included in this transversal study.
Fifty–nine patients were in sinus rhythm (SR) and 38 in permanent AF.
Plasma fluorescent AGEs and soluble RAGE (sRAGE) were measured and comparisons between patients with and without AF were performed.
A multivariate logistic regression analysis was made to define the independent factors associated with AF.
Fluorescent AGEs and sRAGE were higher in AF group (74.9±25.6 vs. 61.8±20.1a.u. for fluorescent AGEs, p=0.006; 1714.2±1105.5 vs. 996.1±820.7pg/mL for sRAGE, p=0.001).
These differences were specially marked in non–diabetic patients.
Both AGEs and sRAGE directly correlated with left atrial dimensions (r=0.496; r=0.536 for atrial area and r=0.491; r=0.511 for atrial volume, for fluorescent AGEs and sRAGE, respectively, p<0.001).
In a multivariate analysis, fluorescent AGEs and sRAGE resulted as markers of AF independent of left atrial distension, diabetes and other confounding variables.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.